ArticleClinical and vaccine immunology : CVI2010
Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation.
Article in Clinical and vaccine immunology : CVI, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 106 citations in OpenAlex.
- Poly(methyl vinyl ether-Polymers · 2026Review
- A modular nanoparticle display strategy for varicella-zoster virus gE based on a licensed protein scaffold.PLoS pathogens · 2026Article
- Use of virus-like particles and nanoparticle-based vaccines for combating picornavirus infections.Veterinary research · 2024Review
- A novel peanut allergy immunotherapy: Plant-based enveloped Ara h 2 Bioparticles activate dendritic cells and polarize T cell responses to Th1.The World Allergy Organization journal · 2023Article
- Polymer Chemistry Defines Adjuvant Properties and Determines the Immune Response against the Antigen or Vaccine.Vaccines · 2023Review
- Current Progress and Challenges in the Study of Adjuvants for Oral Vaccines.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023Review
- Self-adjuvanting cancer nanovaccines.Journal of nanobiotechnology · 2022Review
- Immune Response after Skin Delivery of a Recombinant Heat-Labile Enterotoxin B Subunit of EnterotoxigenicPharmaceutics · 2022Article
- Bioengineering Strategies for Developing Vaccines against Respiratory Viral Diseases.Clinical microbiology reviews · 2022Review
- Oral Immunogenicity of EnterotoxigenicPharmaceutics · 2022Article
- Myeloid cell reprogramming alleviates immunosuppression and promotes clearance of metastatic lesions.Frontiers in oncology · 2022Article
- Peptide-Based Vaccines for Tuberculosis.Frontiers in immunology · 2022Review
- A Novel Approach againstVaccines · 2021Review
- Prophylactic vaccine delivery systems against epidemic infectious diseases.Advanced drug delivery reviews · 2021Review
- Protection Conferred by Drinking Water Administration of a Nanoparticle-Based Vaccine againstVaccines · 2021Article
- Polymeric Nanoparticle-Based Vaccine Adjuvants and Delivery Vehicles.Current topics in microbiology and immunology · 2021Review
- Article
- Protective Passive Immunity inVaccines · 2020Article
- Applications of Nanovaccines for Disease Prevention in Cattle.Frontiers in bioengineering and biotechnology · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The mechanisms that underlie the potent Th1-adjuvant capacity of poly(methyl vinyl ether-co-maleic anhydride) nanoparticles (NPs) were investigated. Traditionally, polymer NPs have been considered delivery systems that promote a closer interaction between antigen and antigen-presenting cells (APCs). Our results revealed that poly(anhydride) NPs also act as agonists of various Toll-like receptors (TLRs) (TLR2, -4, and -5), triggering a Th1-profile cytokine release (gamma interferon [IFN-gamma], 478 pg/ml versus 39.6 pg/ml from negative control; interleukin-12 [IL-12], 40 pg/ml versus 7.2 pg/ml from negative control) and, after incubation with dendritic cells, inducing a 2.5- to 3.5-fold increase of CD54 and CD86 costimulatory molecule expression. Furthermore, in vivo studies suggest that NPs actively elicit a CD8(+) T-cell response. Immunization with empty NPs resulted in a significant delay in the mean survival date (from day 7 until day 23 postchallenge) and a protection level of 30% after challenge against a lethal dose of Salmonella enterica serovar Enteritidis. Taken together, our results provide a better understanding of how NPs act as active Th1 adjuvants in immunoprophylaxis and immunotherapy through TLR exploitation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.